Please assess the completion status of the following clinical trial:

Trial Title: PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males or females between 18 and 65 years; women of childbearing potential must be willing to adhere to lifestyle requirements regarding contraception/pregnancy prevention.~* Newly diagnosed sputum smear-positive pulmonary TB confirmed with acid-fast bacillus (AFB) smear and chest x-ray. Patients with TB more than 5 years ago who completed treatment, are healthy, and meet other inclusion criteria may be included.~* Body weight between 40 and 90 kg, inclusive (in light clothing, no shoes).~* Reasonably normal hemoglobin (\>=8 gm/dL), renal function (serum creatinine \<2 mg/dL), hepatic function (serum AST \<3xULN and total bilirubin \<1.3 mg/dL), and random glucose \<150 mg/dL.~Exclusion Criteria:~* HIV infection with helper/inducer T-lymphocytes (CD4 cell) count of \<=350x10-6/L.~* Presence of significant hemoptysis. Subjects who cough up frank blood (more than blood streaked sputum) will not be eligible.~* Pregnant or nursing females; females of childbearing potential unwilling or unable to adhere to contraception guidelines.~* Significant respiratory impairment (respiratory rate \>35/minute).~* Clinical suspicion of disseminated TB or tuberculosis meningitis.~* Subjects with diabetes mellitus on insulin and/or who have poorly controlled disease.~* Subjects with confirmed or suspected multi-drug resistant TB.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PNU-100480 600 mg BID (Type: EXPERIMENTAL): None
- PNU-100480 1200 mg QD (Type: EXPERIMENTAL): None
- RHZE (Type: ACTIVE_COMPARATOR): conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally

Based on this trial design, predict the completion outcome and termination type (if applicable).